H epatitis C virus (HCV) infection is the most common hepatotropic viral infection that affects patients on maintenance hemodialysis (MHD).
Its prevalence in patients on MHD ranges from 6% to 60% in different parts of the world. In India, various studies have shown a prevalence of HCV in hemodialysis from 4.3% to 45%. 1, 2 Nosocomial transmission and transmission through blood and blood components are 2 important factors that affect HCV incidence. 3, 4 We have also shown that chronic liver disease is an important cause of mortality in renal transplantation at our center. 5 HCV also increases the risk of serious infection in renal transplantation patients. 6 Because HCV infection has been a major issue in many dialysis units in India, these patients are isolated in addition to practicing universal precautions, 7 because dialysis personnel have been reported to be noncompliant with universal precautions. 8 Despite all of these precautions, significant numbers of patients do develop new HCV infection. Kidney Disease Improving Global Outcomes guidelines have suggested treatment with standard interferon (IFN) before transplantation, although the evidence for the recommendation is weak. 9 We showed a 54% sustained virological response (SVR) in our patients while using pegylated IFN monotherapy with no impact of genotype on SVR, although treatment was limited by significant side effects in these patients. 10 With the development of direct antiviral agents (DAAs), therapy for HCV has been revolutionized. However, there are 2 issues related to DAAs. First, various DAA drugs are not universally available in all countries. Second, doses and safety for all DAAs, particularly sofosbuvir (SOF) in stages IV and V chronic kidney disease (CKD) (glomerular filtration rate <30 ml/min) or during MHD is unclear. In India, only SOF and subsequently daclatasvir were available in 2015 to 2016. Because of suboptimal SVR, higher cost, and the moderate degree of adverse effects of IFN-based therapy, there was an intense interest in using DAAs in patients with endstage renal disease and patients on MHD. We report the first experience of DAA therapy in patients in India who were on MHD and who were awaiting renal transplant.
MATERIALS AND METHODS
All patients with HCV infection at our hospital with end-stage renal disease who underwent renal replacement therapy (RRT) and who were treated with DAAs were included in the present study. Handling of HCVinfected patients was previously described in detail. 10 Patients with positive anti-HCV antibodies were further investigated for their qualitative HCV RNA, HCV viral load, and HCV genotype as described previously. 10 Because of our previous experience of only 1 patient with histological cirrhosis, 11 we clinically assessed the activity of liver disease, and no patient underwent liver biopsy. Before starting treatment, hemoglobin, total leukocyte count, differential leukocyte count, platelets, reticulocyte counts, and alpha fetoprotein were assessed in all patients using standard methods. The timing of HCV infection was considered the time since the alanine aminotransferase levels were high above the normal limit or anti-HCV was positive, whichever was earlier. Diagnosis of HCV, polymerase chain reaction, and genotype testing were described previously. 10 Liver fibrosis was measured noninvasively by transient elastography (Fibroscan, Echosens, Paris, France), and the liver stiffness measurement was expressed in kilopascals. A cutoff value of <6 kPa for the liver stiffness measurement excluded fibrosis, and >9 kPa for the liver stiffness measurement was regarded as significant fibrosis. Hepatic steatosis was measured by controlled attenuation parameters, and a value of $250 dB/m indicated significant steatosis.
In response to the initial safety and efficacy data using a full dose of SOF in dialysis patients, 12 after the first few patients (n ¼ 45), we increased the dose to 400 mg/d for the remainder of the cohort. 13 After a few months, daclatasvir became available in India, and we started using daclatasvir 60 mg/d with SOF 400 mg/d in all our patients with all genotypes. All patients were asked to contact their primary caregiver (SKA) if they had any adverse symptoms. For the initial 2 weeks, all biochemical tests were repeated weekly; after that, tests were done as per clinical indications. Patients were followed weekly for the first month, biweekly in the second month, and then at the end of third month.
The first quantitative HCV RNA was assessed between the seventh and fifteenth day after the start of treatment. Subsequent HCV RNA was done at the end of first month, at the end of therapy, and 12 weeks after the stoppage of treatment. Initially, we waited for therapy to be completed before renal transplant was done. However, considering the superior safety profile of these drugs in the post-transplantation period, treatment was also continued in the perioperative period.
RESULTS
From June 2015 to September 2016, 62 treatment-naïve patients were treated with various DAA regimens. Table 1 There was no difference in response rates in relation to genotype. Three patients who relapsed had 1 each of the 1, 3a, and 4 genotypes. Twenty-three patients (37%) had complications while on therapy. Thirteen (20.3%) patients had dyspepsia after start of treatment. Most of the patients (23 of 41; 56%) in the ribavirin group required an increase in mean weekly erythropoietin doses of 12,000 AE 1873 U (range: 10,000-16,000 U), with or without injectable iron therapy. Three patients required blood transfusion. Patients who were not on ribavirin did not require an increase in erythropoietin doses.
The maximum dose of erythropoietin given was 16,000 U/week in 5 patients. None of the patients had any other biochemical abnormality attributed to drug treatment. Four patients developed tuberculosis, and 3 experienced bacterial pneumonias; all of these patients were treated appropriately. None of the patients discontinued therapy due to side effects. Of the treated patients, 22 had undergone renal transplant at the time of writing this paper.
DISCUSSION
This is the first report on the experience of DAAs in patients on MHD from India and the largest single-center experience on SOF-based therapy in hemodialysis patients. Considering the efficacy and safety of these drugs in these patients, management of HCV-infected patients in hemodialysis is going to change dramatically. This is much more relevant in a country like India, where in some dialysis units, HCV infection prevalence is still >50% (unpublished data).
A recently published meta-analysis showed that there were 11 studies on the efficacy of DAAs in 264 patients on MHD, including 1 multicenter study that enrolled 122 patients (Table 3) . [14] [15] [16] [17] [18] [19] [20] The SVR in all these studies 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] ranged between 66.7% and 98.3%, with a pooled SVR of 93.2%. For several subgroup populations, SVR in SOF-based therapy was 89.4%. For genotype 1 patients, the pooled SVR rate at 12 weeks was 93.1%. Nineteen patients in 2 studies were treated with a half-dose of SOF, and 4 of them failed to reach SVR rate at 12 weeks, suggesting that the SOF dose may be an important variable for SVR. In addition, in our patient group, all 3 patients who relapsed after DCV, daclatasvir; DSV, dasabuvir; LDV, ledipasvir; OBV, ombitasvir; PR, pegylated interferon combined with ribavirin; PTV, paritaprevir; RBV, ribavirin; SM, simeprevir; SOF, sofosbuvir.
completion of therapy were on 400 mg alternate day SOF treatment. Desnoyer et al. 13 showed that SOF and its active metabolites did not accumulate in patients on hemodialysis and suggested use of 400 mg/d SOF with close monitoring. Available literature and our own experience showed excellent efficacy of various DAAs, including SOF-based therapy in HCV patients on hemodialysis, with a SVR close to 90% in most studies. In many studies, the most common genotype was genotype 1. Genotype 1 was also seen in 64.5% of patients, followed by genotype 3 in 29% of cases in the present study. Genotypes 2 and 6 were seen in 2 patients, respectively, and genotype 4 was found in 2 patients.
With such excellent efficacy, the next issue of concern is safety. The present study also showed excellent safety, with an increase in dyspepsia being the only frequent side effect. In patients on hemodialysis, dyspepsia might not always be attributed to drug therapy. There was no difference in dyspepsia whether patients were on SOF 400 mg alternate day or daily therapy. Patients who were on ribavirin therapy did require an increase in erythropoietin dose, which was not unexpected. We were forced to use ribavirin because other DAAs were not available initially. Once daclatasvir became available, we substituted this medication in combination with SOF and stopped using ribavirin. Previous studies showed serious adverse events ranging from 0% to 50% of patients. There are many issues to be taken into account when interpreting side effects in these studies. First, the number of patients in many of these studies were few, which could distort interpretation of the percentage of side effects. Second, except for 2 studies, 17, 18 all others had patients with cirrhosis (range: 40%À80%). In the present study, no patient had clinical cirrhosis (normal endoscopy in all), although we did not perform liver biopsies in any of the patients. Third, in many of these studies, previous treatment had failed in patients with HCV. Fourth, almost all studies had used treatment with DAAs in addition to SOF, making it difficult to interpret which drug was responsible for the side effects.
Currently, in many countries, HCV during dialysis is a major problem; in many of these countries, availability of DAAs and costs of drugs are also an issue. Patients with ESRD usually do not have cirrhosis because most of the time this is a contraindication for an isolated renal transplantation, which nephrologists supervise. This makes handling of DAAs in this clinical setting easy because some of the DAAs (e.g., protease inhibitors) are not recommended in decompensated cirrhosis. Furthermore, SOF not only can be used in the presence of cirrhosis, but it is also a pan-genotype DAA and is the most important DAA for treatment of HCV patients in any setting. In the absence of clear-cut guidelines for the use of SOF in dialysis patients, many clinicians hesitate to use SOF-based therapy. Considering this ambiguity about SOF use in MHD patients, we are sharing our large single-center experience of the excellent safety and efficacy of SOF in these patients.
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